Through ClientSite you can filter variants and download your reports
MammaPrint® + BluePrint®
Every woman deserves a unique treatment strategy
For LN+ patients
MammaPrint® helps you to understand the metastatic potential of each tumor.
For patiens with node-positive (LN+) and node-negative (LN-) tumors.
Period or no period
MammaPrint® is effective to identify very low-risk tumors that would not benefit from chemotherapy in premenopausal women ≤50 years old. It helps to avoid overtreatment.
Latest news
Updated NCCN guidelines recognize MammaPrint® UltraLow Risk outcome for de-escalating treatment of patients with early breast cancer.
MammaPrint® + BluePrint® together help address the complexity of early breast cancer
Are you receiving the complete information to make timely decisions about the optimal treatment?
1 in 8 women will be diagnosed with breast cancer in her lifetime.
Treatment plan information is crucial to improving patient outcomes and management.
More than 33,000 new cases of breast cancer in Spain in 2019
What do we offer you as valuable information for decision making?
MammaPrint®
Relapse risk test
MammaPrint®, 70-gene breast cancer relapse test, is the first FDA approved and CE marked test, supported by peer-reviewed data from prospective studies included in major treatment guidelines.
BluePrint®
Functional molecular subtyping
BluePrint®, the 80-gene molecular substaging test, goes beyond the surface cells, evaluating the underlying biology that drives tumor growth.
-
BluePrint® identifies the underlying biology driving tumor growth and enables more accurate molecular substaging to be identified
-
Approximately 1 in 5 pathologically RH+ women are reclassified to Basal Type-High Risk tumors
Learn more about MammaPrint® and BluePrint®
Patient cases
How to request it?
Download brochure MammaPrint® + BluePrint®